The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory ...

The agreement will give Kuro enough capital to support the development and launch of its menin inhibitor ziftomenib.

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

including null or point mutations and complex chromosomal rearrangements such as large deletions, translocations, or inversions (Bedell et al., 1997a). Many knock-out and knock-in mice have ...

Mutations in the genes encoding the E3 ligase ... “We also found that Parkin translocation to mitochondria will activate elimination of damaged mitochondria by autophagy, suggesting that Parkin ...

An estimated 95% ofKMT2Ar acute leukemia patients have KMT2A translocation. This abnormality is seen in about 10% of all leukemias. Only about 5% of patients with this mutation achieve complete ...

Given the complexity of this genetic information (e.g., tumor mutation and gene overexpression, chromosomal translocation and germline variations), as well as the variable level of scientific ...